International consortium to get to heart of coronary artery disease

7 February 2007

An international consortium has been launched to tackle coronary artery disease using the latest scientific tools. Funded by the European Commission, the initiative will build on recent advances in genomic science and the understanding of our genes to develop effective strategies for preventing and treating the disease.

Coronary artery disease (CAD) is the most common form of heart disease in Europe and the US. It is caused by a narrowing of the arteries due to deposits of fat and cholesterol, preventing enough blood reaching the heart. Symptoms include chest pain, shortness of breath and numbness in the arms and shoulders, and the disease can lead to heart attack.

However, while scientists know that high-fat and high-cholesterol diets play a significant role in the disease, they do not understand fully what makes some people more susceptible to the disease than others. They believe that many factors contribute, both environmental and genetic.

"Coronary artery disease is a major health issue in the Western world and we want to get to the root of what causes it," says Professor Dominique Gauguier from the Wellcome Trust Centre for Human Genetics at the University of Oxford. "It is a complex disease, so it's impossible to say 'We've found the gene for CAD'. Rather, it is caused by a number of factors, including the interaction of genes with other genes and with the environment."

Professor Gauguier, a Wellcome Trust Senior Research Fellow, is leading an international consortium known as Functional Genomic Diagnostic Tools for Coronary Artery Disease (FGENTCARD). The project, which has received €3 million over three years from the European Commission, involves academic and industrial scientists from the UK, France, Denmark and Lebanon.

The consortium will use the latest technologies for analysing DNA to identify those at risk from CAD. These include functional genomics - taking a sequence of the genome and analysing the function of individual genes and their interaction with other genes to understand the role they play in disease.

Among other things, the study will look at the extent to which CAD risk factors, such as insulin resistance, hypertension and obesity, can be predicted using biomarkers in the blood. Scientists have already identified biomarkers, which, when found in elevated levels, indicate the presence of certain types of tumour.

In addition, Professor Gauguier hopes that the study will offer an insight into tackling other complex diseases through therapeutic and strategic means.

"We believe the study will play a key role in identifying targets for novel therapies to tackle the disease," says Professor Gauguier. "Ultimately, we hope that the wealth of information obtained by the project and the techniques that it helps us develop will lead to significant advances for disease diagnosis and prevention."

FGENTCARD builds on previous Wellcome Trust-funded research including BAIR (the Biological Atlas of Insulin Resistance) and CFG (the Cardiovascular Functional Genomics consortium).

Contact

Craig Brierley
Media Officer
Wellcome Trust
T +44 (0)20 7611 7329
E c.brierley@wellcome.ac.uk

Notes for editors

1. The Wellcome Trust is the largest independent charity in the UK and the second largest medical research charity in the world. It funds innovative biomedical research, in the UK and internationally, spending around £500 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing.

2. FGENTCARD involves four academic laboratories in the UK (University of Oxford and Imperial College London), France (Centre National de Génotypage) and Lebanon (American University of Beirut), and three industrial laboratories in Denmark (NOVO Nordisk), France (IntegraGen SA) and the UK (Metabometrix Ltd).